PT - JOURNAL ARTICLE AU - Yushi Nomura AU - Michiru Sawahata AU - Yosikazu Nakamura AU - Ryousuke Koike AU - Otohiro Katsube AU - Koichi Hagiwara AU - Seiji Niho AU - Norihiro Masuda AU - Takaaki Tanaka AU - Kumiya Sugiyama TI - Attenuation of antibody titres during 3-6 months after the second dose of the BNT162b2 vaccine depends on sex, with age and smoking as risk factors for lower antibody titres at 6 months AID - 10.1101/2021.11.14.21266334 DP - 2021 Jan 01 TA - medRxiv PG - 2021.11.14.21266334 4099 - http://medrxiv.org/content/early/2021/11/17/2021.11.14.21266334.short 4100 - http://medrxiv.org/content/early/2021/11/17/2021.11.14.21266334.full AB - Objective We aimed to determine antibody titres at 6 months and their rate of change during 3-6 months after the second dose of the BNT162b2 coronavirus disease 2019 (COVID-19) mRNA vaccine (Pfizer/BioNTech) and to explore clinical variables associated with titres in Japan.Methods We enrolled 365 healthcare workers (250 women, 115 men) whose 3-month antibody titres were analyzed in our previous study and whose blood samples were collected 183 ± 15 days after the second dose. Participant characteristics collected previously were used. The relationships of these factors with antibody titres at 6 months and rates of change in antibody titres during 3-6 months were analyzed.Results Median age was 44 years. Median antibody titre at 6 months was 539 U/mL. Older participants had significantly lower antibody titres (20s, 752 U/mL; 60s–70s, 365 U/mL). In age-adjusted analysis, smoking was the only factor associated with lower antibody titres. Median rate of change in antibody titres during 3-6 months was −29.4%. The only factor significantly associated with the rate of change in Ab titres was not age or smoking, but sex (women, −31.6%; men, −25.1%).Conclusion The most important factors associated with lower antibody titres at 6 months were age and smoking, as at 3 months, probably reflecting their effect on peak antibody titres. However, antibody titres significantly attenuated during 3-6 months in women alone, which reduced the sex difference in antibody titres seen during the first 3 months. Antibody titres may be affected by different factors at different time points.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of National Hospital Organization Utsunomiya National Hospital gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscriptCOVID-19coronavirus disease 2019AbantibodyIQRinterquartile rangeSARS-CoV-2severe acute respiratory syndrome coronavirus 2